Current indications of voriconazole in onco-hematological patients;Indicaciones actuates de voriconazol en pacientes onco-hematológicos

Revista Iberoamericana de Micologia

Volumn 24, Issue 3, 2007, Pages 213-216

  Jarque, Isidro ^a   Sanz, Miguel A ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Empirical therapy; Febrile neutropenia; Hematological malignancies; Hematopoietic transplant; Prophylaxis; Voriconazole

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; CYTOCHROME P450 3A4; FLUCONAZOLE; LIVER ENZYME; TRIAZOLE; VORICONAZOLE; AMPHOTERICIN B; ANTIFUNGAL AGENT; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ACREMONIUM; ANTIBIOTIC RESISTANCE; ASPERGILLOSIS; CANDIDEMIA; CAUSE OF DEATH; CLINICAL PRACTICE; DRUG APPROVAL; DRUG INDICATION; FEBRILE NEUTROPENIA; FUSARIUM; HEMATOLOGIC MALIGNANCY; HUMAN; INFECTION PREVENTION; LONG TERM CARE; MOULD; MUCORMYCOSIS; MYCOSIS; NEUTROPENIA; REVIEW; SCEDOSPORIUM; SECONDARY PREVENTION; TRANSPLANTATION; TRICHOSPORON; ZYGOMYCETES; ANTIBIOTIC PROPHYLAXIS; ANTIFUNGAL RESISTANCE; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNE DEFICIENCY; MICROBIOLOGY; MULTICENTER STUDY; NEOPLASM; OPPORTUNISTIC INFECTION; RANDOMIZED CONTROLLED TRIAL; SALVAGE THERAPY; SPAIN;

CANDIDA; FUNGI; FUSARIUM; SCEDOSPORIUM;

AMPHOTERICIN B; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTICS, ANTIFUNGAL; DRUG RESISTANCE, FUNGAL; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; MULTICENTER STUDIES AS TOPIC; MYCOSES; NEOPLASMS; NEUTROPENIA; OPPORTUNISTIC INFECTIONS; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SALVAGE THERAPY; SPAIN; TRIAZOLES; ZYGOMYCOSIS;

EID: 35348994955     PISSN: 11301406     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1130-1406(07)70045-1     Document Type: Review

References (54)

1. Antachopoulos C, Papakonstantinou E, Dotis J, Bibashi E, Tamiolaki M, Koliouskas D, Roilides E. Fungemia due to Trichosporon asahii in a neutropenic child refractory to amphotericin B: clearance with voriconazole. J Pediatr Hematol Oncol 2005; 27: 283-285.
2. Apostolova LG, Johnson EK, Adams HP. Disseminated Pseudallescheria boydii infection successfully treated with voriconazole. J Neurol Neurosurg Psychiatr 2005; 76: 1741-1742.
3. Asada N, Uryu H, Koseki M, Takeuchi M, Komatsu M, Matsue K. Successful treatment of breakthrough Trichosporon asahii fungemia with voriconazole in a patient with acute myeloid leukemia. Clin Infect Dis 2006; 43: e39-e41.
4. Athanassiadou F, Tragiannidis A, Kourti M, Papageorgiou T, Velegraki A, Kalogera A. Treatment of disseminated aspergillosis with voriconazole/liposomal amphotericin B in a child with leukemia. Pediatr Blood Cancer 2005; 45: 1003-1004.
5. Azzola A, Passweg JR, Habicht JM, Bubendorf L, Tamm M, Gratwohl A, Eich G. Use of lung resection and voriconazole for successful treatment of invasive pulmonary Aspergillus ustus infection. J Clin Microbiol 2004; 42: 4805-4808.
6. Bethge WA, Schmalzing M, Stuhler G, Schumacher U, Krober SM, Horger M, Einsele H, Kanz L, Hebart H. Mucormycoses in patients with hematologic malignancies: an emerging fungal infection. Haematologica 2005; 90: ECR22 [documento electrónico].
7. Bigley VH, Duarte RF, Gosling RD, Kibbler CC, Seaton S, Potter M. Fusarium dimerum infection in a stem cell transplant recipient treated successfully with voriconazole. Bone Marrow Transplant 2004; 34: 815-817.
8. Chamilos G, Luna M, Lewis RE, Bodey GP, Chemaly R, Tarrand JJ, Safdar A, Raad II, Kontoyiannis DP. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 2006; 91: 986-989.
9. Consigny S, Dhedin N, Datry A, Choquet S, Leblond V, Chosidow O. Successful voriconazole treatment of disseminated Fusarium infection in an immunocompromised patient. Clin Infect Dis 2003; 37: 311-313.
10. Cordonnier C, Maury S, Pautas C, Bastie JN, Chehata S, Castaigne S, Kuentz M, Bretagne S, Ribaud P. Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. Bone Marrow Transplant 2004; 33: 943-948.
11. Dasbach EJ, Davies GM, Teutsch SM. Burden of aspergillosis-related hospitalizations in the United States. Clin Infect Dis 2000; 31: 1524-1528.
12. Denning DW. Antifungal and surgical treatment of invasive aspergillosis: review of 2121 published cases. Rev Infect Dis 1997; 12: 1147-1201.
13. Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, Haas A, Ruhnke M, Lode H. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002, 34: 563-571.
14. Girmenia C, Pagano L, Corvatta L, Mele L, del Favero A, Martino P. The epidemiology of fusariosis in patients with haematological diseases. GIMEMA Infection Programme. Br J Haematol 2000; 11: 272-276.
15. Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996; 33: 23-32.
16. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B; Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002, 347: 408-415.
17. Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004; 39: 743-746.
18. Kami M, Machida U, Okuzumi K, Matsumura T, Mori Si S, Hori A, Kashima T, Kanda Y, Takaue Y, Sakamaki H, Hirai H, Yoneyama A, Mutou Y. Effect of fluconazole prophylaxis on fungal blood cultures: an autopsy-based study involving 720 patients with haematological malignancy. Br J Haematol 2002; 117: 40-46.
19. Kauffman CA. Zygomycosis: reemergence of an old pathogen. Clin Infect Dis 2004; 39: 588-590.
20. Klastersky J. Antifungal therapy in patients with fever and neutropenia-more rational and less empirical? N Engl J Med 2004; 351: 1445-1447.
21. Kontoyiannis DP, Bodey GP. Invasive aspergillosis in 2002: an update. Eur J Clin Microbiol Infect Dis 2002; 21: 171-172.
22. Kontoyiannis DP, Lionakis MS, Lewis RE, Chamilos G, Healy M, Perego C, Safdar A, Kantarjian H, Champlin R, Walsh TJ, Raad II. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005; 191: 1350-1360.
23. La Nasa G, Littera R, Maccioni A, Ledda A, Vacce A, Contu L. Voriconazole for the treatment of disseminated nodular cutaneous aspergillosis in a patient affected by acute myeloid leukemia. Hematol J 2004; 5: 178-180.
24. Less-Flörl C, Fille M, Gunsilius E, Gastl G, Nachbaur D. Disseminated infection with Prototheca zopfii after unrelated stem cell transplantation for leukemia. J Clin Microbiol 2004; 42: 4907-4908.
25. Lass-Flörl C, Griff K, Mayr A, Petzer A, Gastl G, Bonatti H, Freund M, Kropshofer G, Dierich MP, Nachbaur D. Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience. Br J Haematol 2005; 131: 201-207.
26. Lin S, Schranz J, Teutsch S. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32: 358-366.
27. Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000; 181: 309-316.
28. Martino R, Salavert M, Parody R, Tomas JF, de la Cámara R, Vázquez L, Jarque I, Prieto E, Sastre JL, Gadea I, Pemán J, Sierra J. Blastoschizomyces capitatus infection in patients with leukemia: report of 26 cases. Clin Infect Dis 2004; 38: 335-341.
29. Mattei D, Mordini N, Lo Nigro C, Gallamini A, Osenda M, Pugno F, Viscoli C. Successful treatment of Acremonium fungemia with voriconazole. Mycoses 2003; 46: 511-514.
30. McNeil MM, Nash SL, Hajjeh RA, Phelan MA, Conn LA, Plikaytis BD, Warnock DW. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 2001; 33: 641-647.
31. Miyakis S, Velegraki A, Delikou S, Parcharidou A, Papadekis V, Kitra V, Papadatos I, Polychronopoulou S. Invasive Acremonium strictum infection in a bone marrow transplant recipient. Pediatr Infect Dis J 2006; 25: 273-275.
32. Oren I. Breakthrough zygomycosis during empirical voriconazole therapy in febrile patients with neutropenia. Clin Infect Dis 2005; 40: 770-771.
33. Pagano L, Girmenia C, Mele L, Ricci P, Tosti ME, Nosari A, Buelli M, Picardi M, Allione B, Corvatta L, D'Antonio D, Montillo M, Melillo L, Chierichini A, Cenacchi A, Tonso A, Cudillo L, Candoni A, Savignano C, Bonini A, Martino R Del Favero A; GIMEMA Infection Program; Gruppo Italiano Malattie Ematologiche dell'Adulto. Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GIMEMA Infection Program. Haematologica 2001; 86: 862-870.
34. Panagopoulou P, Filioti J, Farmaki E, Maloukou A, Roilides E. Filamentous fungi in a tertiary care hospital: environmental surveillance and susceptibility to antifungal drugs. Infect Control Hosp Epidemiol 2007; 28: 60-67.
35. Pavie J, Lacroix C, Hermoso DG, Robin M, Ferry C, Bergeron A, Feuilhade M, Dromer F, Gluckman E, Molina JM, Ribaud P. Breakthrough disseminated Aspergillus ustus infection in allogeneic hematopoietic stem cell transplant recipients receiving voriconazole or caspofungin prophylaxis. J Clin Microbiol 2005; 43: 4902-4904.
36. Perfect JR, Marr KA, Walsh TJ, Greenberg RN, DuPont B, de la Torre-Cisneros J, Just-Nübling G, Schlamm HT, Lutsar I, Espinel-Ingroff A, Johnson E. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36: 1122-1131.
37. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, Sein M, Sein T, Chiou CC, Chu JH, Kontoyiannis DP, Walsh TJ. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41: 634-653.
38. Sagnelli C, Fumagalli L, Prigitano A, Baccari P, Magnani P, Lazzarin A. Successful voriconazole therapy of disseminated Fusarium verticillioides infection in an immunocompromised patient receiving chemotherapy. J Antimicrob Chemother 2006; 57: 796-798.
39. Saitoh T, Matsushima T, Shimizu H, Yokohama A, Irisawa H, Handa H, Tsukamoto N, Karasawa M, Nojima Y, Murakami H. Successful treatment with voriconazole of Aspergillus meningitis in a patient with acute myeloid leukemia. Ann Hematol 2007; en prensa.
40. Salavert M, Jarque I, Pemán J. Los aspectos epidemiológicos cambiantes de la candidemia y sus implicaciones clinicoterapéuticas. Enf Infec Microbiol Clin 2006; 24 (Supl. 1): 36-45.
41. Sanz MA, Jarque I, Salavert M, Pemán J. Epidemiology of invasive fungal infections due to Aspergillus spp. and Zygomycetes. Clin Microbiol Infect 2006; 12 (Supl. 7): 2-6.
42. Siwek GT, Pfaller MA, Polgreen PM, Cobb S, Hoth P, Magalheas-Silverman M, Diekema DJ. Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis. Diagn Microbiol Infect Dis 2006; 55: 209-212.
43. Stanzani M, Vianelli N, Bandini G, Paolini S, Arpinati M, Bonifazi F, Giannini B, Agostinelli C, Baccarani M, Ricci P. Successful treatment of disseminated fusariosis after allogeneic hematopoietic stem cell transplantation with the combination of voriconazole and liposomal amphotericin B. J Infect 2006; 53: e243-e246.
44. Steinbach WJ, Benjamin DK, Kontoyiannis DP, Perfect JR, Lutsar I, Marr KA, Lionakis MS, Torres HA, Jafri H, Walsh TJ. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis 2004; 39: 192-198.
45. Strasfeld L, Weinstock DM. Antifungal prophylaxis among allogeneic hematopoietic stem cell transplant recipients: current issues and new agents. Expert Rev Anti Infect Ther 2006; 4: 457-468.
46. Trifilio S, Pennick G, Pi J, Zook J, Golf M, Kaniecki K, Singhal S, Williams S, Winter J, Tallman M, Gordon L, Frankfurt O, Evens A, Mehta J. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 2007; 109: 1532-1535.
47. Trifilio SM, Bennett CL, Yarnold PR, McKoy JM, Parada J, Mehta J, Chamilos G, Palella F, Kennedy L, Mullane K, Tallman MS, Evens A, Scheetz MH, Blum W, Kontoyiannis DP. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 2007; 39: 425-429.
48. Vagace JM, Sanz-Rodriguez C, Casado MS, Alonso N, Garcia-Dominguez M, Garcia de la Llane F, Zarallo L, Fajardo M, Bajo R. Resolution of disseminated fusariosis in a child with acute leukemia treated with combined antifungal therapy: a case report. BMC Infect Dis 2007; 7: 40.
49. van Well GT, van Groeningen I, Debets-Ossenkopp YJ, van Furth AM, Zwaan CM. Zygomycete infection following voriconazole prophylaxis. Lancet Infect Dis 2005; 5: 594.
50. Vigouroux S, Morin O, Moreau P, Méchinaud F, Morineau N, Mahé B, Chevallier P, Guillaume T, Dubruille V, Harousseau JL, Milpied N. Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required. Clin Infect Dis 2005; 40: e35-e37.
51. Vincent AL, Cabrero JE, Greene JN, Sandin RL. Successful voriconazole therapy of disseminated Fusarium solani in the brain of a neutropenic cancer patient. Cancer Control 2003; 10: 414-419.
52. Wandroo F, Stableforth P, Hasan Y. Aspergillus brain abscess in a patient with acute myeloid leukaemia successfully treated with voriconazole. Clin Lab Haematol 2006; 28: 130-133.
53. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, Yanovich S, Stiff P, Greenberg R, Donowitz G, Schuster M, Reboli A, Wingard J, Arndt C, Reinhardt J, Hadley S, Finberg R, Laverdière M, Perfect J, Garber G, Fioritoni G, Anaissie E, Lee J; National Institute of Allergy and Infectious Diseases Mycoses Study Group. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346: 225-234.
54. Yamazaki T, Kume H, Murase S, Yamashita E, Arisawa M. Epidemiology of visceral mycoses: analysis of data in annual of the pathological autopsy cases in Japan. J Clin Microbiol 1999; 37: 1732-1738.